BMS-986442 + Nivolumab for Lung Cancer
Trial Summary
What is the purpose of this trial?
This trial is testing a new drug called BMS-986442 together with nivolumab, and sometimes chemotherapy, to see if it can help fight cancer more effectively.
Will I have to stop taking my current medications?
The trial information does not specify if you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What data supports the effectiveness of the drug Nivolumab for lung cancer?
Nivolumab has been shown to significantly improve overall survival and progression-free survival in patients with advanced squamous non-small cell lung cancer (NSCLC) compared to docetaxel, as demonstrated in the CheckMate 017 trial. It is also better tolerated, making it an important option for previously-treated advanced NSCLC.12345
Is the combination of BMS-986442 and Nivolumab safe for humans?
What makes the drug combination of BMS-986442 and Nivolumab unique for lung cancer treatment?
The combination of BMS-986442 and Nivolumab is unique because Nivolumab is a PD-1 immune checkpoint inhibitor that has shown improved survival rates in advanced lung cancer, and combining it with BMS-986442 may enhance its effectiveness by potentially targeting different pathways in the immune system.12378
Research Team
Bristol-Myers Squibb
Principal Investigator
Bristol-Myers Squibb
Eligibility Criteria
This trial is for adults with certain types of lung or solid tumors who are in fairly good physical condition (able to carry out daily activities with ease or minor limitations) and expected to live at least 3 more months. They must have measurable tumor growth that can be tracked over time. People with untreated brain metastases, another cancer needing treatment, or active autoimmune diseases cannot join.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive BMS-986442 in combination with nivolumab, with or without chemotherapy, for antitumor efficacy
Dose Limiting Toxicity Evaluation
Evaluation of dose limiting toxicities within the first 28 days of treatment
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- BMS-986442
- Carboplatin
- Docetaxel
- Nivolumab
- Paclitaxel
- Pemexetred
Find a Clinic Near You
Who Is Running the Clinical Trial?
Bristol-Myers Squibb
Lead Sponsor
Christopher Boerner
Bristol-Myers Squibb
Chief Executive Officer since 2023
PhD in Business Administration from the Haas School of Business, University of California, Berkeley; BA in Economics and History from Washington University in St. Louis
Deepak L. Bhatt
Bristol-Myers Squibb
Chief Medical Officer since 2024
MD from Yale University; MSc in Clinical Epidemiology from the University of Pennsylvania